Amsterdam, the Netherlands and Stevenage, UK – 4 November 2024 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Dr. Lara Boyd as Chief Business Officer. Lara joins Tessellate BIO from F-star Therapeutics, an innovation focused biotech company dedicated to delivering next-generation multispecific […]
Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian pediatric medical research institute, and Omico, an organization uniting over 50 world-class cancer institutes in Australia and New Zealand. The collaboration has […]
Amsterdam, the Netherlands and London, UK – 1 May 2024 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Professor Sandra Strauss, University College London, to its Scientific Advisory Board. The SAB, which recently convened a successful meeting in San Diego ahead of the […]
Amsterdam, the Netherlands and London, UK – 15 November 2023 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board. A key part of Tessellate BIO’s strategy is to source cutting-edge research from international world-renowned laboratories to […]
The Next Generation Synthetic Lethality Precision Oncology Company The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complex Company backed by leading venture firms, BioGeneration Ventures (BGV) and Forbion World-class […]
© Tessellate Bio
